Description:
This study is designed to evaluate the efficacy and safety of Pyrotinib in patients of
advanced pre-treated Non-small cell lung cancer With HER2 Mutation.
To observe objective response rate (ORR) of pyrotinib in NSCLC With HER2 Mutation. To observe
Progression free survival (PFS). To assess the overall survival (OS).
A secondary aim is to obtain safety information.
To explore the relationship between biomarkers and the toxicity/efficacy of Pyrotinib.
Title
- Brief Title: A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation
- Official Title: A Phase 2 Clinica Study: Efficacy and Safety of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation
Clinical Trial IDs
- ORG STUDY ID:
HR-BLTN-Ⅱ-NSCLC
- NCT ID:
NCT02834936
Conditions
Interventions
Drug | Synonyms | Arms |
---|
pyrotinib | BLTN | pyrotinib treatment |
Purpose
This study is designed to evaluate the efficacy and safety of Pyrotinib in patients of
advanced pre-treated Non-small cell lung cancer With HER2 Mutation.
To observe objective response rate (ORR) of pyrotinib in NSCLC With HER2 Mutation. To observe
Progression free survival (PFS). To assess the overall survival (OS).
A secondary aim is to obtain safety information.
To explore the relationship between biomarkers and the toxicity/efficacy of Pyrotinib.
Trial Arms
Name | Type | Description | Interventions |
---|
pyrotinib treatment | Experimental | | |
Eligibility Criteria
Inclusion Criteria:
1. ECOG performance status of 0 to 1.
2. Life expectancy of more than 3 months.
3. At least one measurable lesion exists.(RECIST 1.1).
4. Histologically or cytologic confirmed Non-small cell lung cancer, Phase IIIB or IV
according to IASLC 2009.
5. Failed prior therapies.(RECIST 1.1).
6. Confirmed HER2 mutation by Central Laboratory。
7. More than one prior Platinum based chemotherapy for advanced and/or metastatic, or
recurrent NSCLC in neoadjuvant or adjuvant chemotherapy.
8. Required laboratory values including following parameters:
ANC: ≥ 1.5 x 10^9/L; Platelet count: ≥ 90 x 10^9/L; Hemoglobin: ≥ 90 g/L; Total
bilirubin: ≤ 1.5 x upper limit of normal (ULN); ALT and AST: ≤2 x ULN or ALT and AST:
≤5x ULN for patients with liver metastasis; BUN and Cr: ≤1.5 x ULN; creatine clearance
rate: ≥ 50 mL/min; LVEF: ≥ 50%; QTcF: < 470 ms for female and < 450 ms for male.
9. Signed informed consent
Exclusion Criteria:
1. Previous therapy with other HER2 inhibitors.
2. History of severe hypersensitivity reactions to the excipients of the trial drugs.
3. Have clinically significant cavity effusion,such as pleural effusion、 pericardial
effusion or ascites and require clinical intervention
4. Active brain metastases
5. Other malignancy within the past (including primary brain tumor or Leptomeningeal
tumor), other than basal cell skin cancer or carcinoma in situ of the cervix
6. Persistence of clinically relevant therapy related toxicities from previous therapy
(greater than Common Terminology Criteria for Adverse Event(CTCAE) 4.0 grade 1)
7. Treatment with surgery, chemotherapy, radiotherapy or other target therapy within the
past 4 weeks before start of therapy
8. Uncontrolled hypertensin,diabetes.
9. unstable angina, history of myocardial infarction in the past 6 months, congestive
heart failure>NYHA II, serious cardiac arrhythmia
10. Active infection
11. Variety of factors that affect the oral medication (such as unable to swallow, chronic
diarrhea, bowel obstruction and other gastrointestinal disorders or abnormalities
12. History of immunodeficiency, including HIV-positive, suffering from other acquired,
congenital immunodeficiency disease, or history of organ transplantation.
13. Subjects had any heart disease, including: (1) angina; (2) requiring medication or
clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5)
Any heart diseases judged by investigator as unsuitable to participate in the trial.
14. Female patients who are pregnancy, lactation or women who are of childbearing
potential tested positive in baseline pregnancy test.
15. Known history of neurological or psychiatric disease, including epilepsy or dementia.
16. Treatment in another clinical trial within the past 4 weeks before start of therapy
17. Any of the other conditions of which researchers believe that the patient is not fit
to take part in the study.
Maximum Eligible Age: | 75 Years |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Objective Response Rate (ORR) |
Time Frame: | tumor assessment every 6-9 weeks after the initiation of pyrotinib, up to 24 months |
Safety Issue: | |
Description: | |
Secondary Outcome Measures
Measure: | Progression Free Survival (PFS) |
Time Frame: | up to 24 months |
Safety Issue: | |
Description: | |
Measure: | Incidence and Intensity of Adverse Events |
Time Frame: | From signing informed consent document until 28 days after the last drug administration |
Safety Issue: | |
Description: | Number of Participants with treatment related Adverse Events as Assessed by CTCAE v4.0 |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Unknown status |
Lead Sponsor: | Jiangsu HengRui Medicine Co., Ltd. |
Last Updated
March 29, 2017